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INTRODUCTION 
 Periodontitis is a common cause of tooth loss and contributes to other 
common conditions. It affects 46% of adult Americans, 8.9% of them severely1. 
Bacteria are essential for initiation, but host factors are crucial for development 
of chronic inflammation. An imbalance exists between inflammatory and anti-
inflammatory cytokines, and increased levels of IL-1β, IL-6 and TNFα activate 
gingival fibroblasts to produce inflammatory mediators including prostaglandin 
E2 (PGE2) and matrix metalloproteinases (MMPs), which contribute to 
continuing inflammation and destruction of tissues supporting teeth2-6.   
 Periodontitis causes a chronic, low-grade systemic inflammation that 
contributes to development of other conditions, including cardiovascular 
disease, pre-term low birth weight, diabetes and several types of cancer7-14. 
Evidence is accumulating that epigenetic changes in inflamed tissues alter gene 
expression patterns to contribute to persistence of inflammation and to the 
predisposition to cancer associated with chronic inflammatory conditions10, 15.   
 Here we show that both inflammatory cytokine IL-1 and inflammatory 
mediator PGE2 inhibit expression of the de novo methyltransferase DNMT3a as 
well as Ten Eleven Translocation 1 (TET1) in human gingival fibroblasts derived 
from patients with periodontitis, and present evidence that the effects of IL-1 
may be mediated at least partly through the COX-2/PGE2 pathway.  The results 
so far are consistent with the idea that chronic exposure of fibroblasts to 
inflammatory signaling can result in changes in DNA methylation/demethylation.  
These changes could result in global and/or gene specific changes which over 
time might contribute to the persistence of inflammation. 
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• These data provide evidence that both IL-1 and PGE2 affect expression of the 
de novo DNA methyltranserase DNMT3a and the demethylating enzyme TET1 
in HGF.   
• Treatment of HGF cultures with PGE2 caused a dose-dependent decrease in 
mRNA levels of DNMT1, DNMT3a and TET1 as compared to untreated 
controls.   
• DNMT3a expression was inhibited by IL-1 regardless of when the control 
sample was isolated, but DNMT1 was induced by IL-1 only as compared to a 
time zero control.  This suggests that expression of DNMT1 is affected by time 
in culture rather than by IL-1 per se.  
• Global levels of DNA methylation increased slightly over 72 hour treatment 
with IL-1 as compared to a time zero control.  This is consistent with the 
changes observed in DNMT1 expression over time, and most likely do not 
reflect changes brought about by IL-1. 
• Although inhibition of COX-2 with NS-398 seemed to partially reverse the 
effects of IL-1 on expression of DNMT3a and TET1, this effect is not 
statistically significant.  It is unclear at this time whether the effects of IL-1 
might be mediated at least partly by increased PGE2 production. 
• Even modest changes in expression of these enzymes, if sustained over time, 
might be expected to have significant effects on gene expression patterns. 
• Further experiments are needed to determine:  
• whether changes in DNMT3a and TET1 mRNA levels in response to IL-1 
and PGE2 are reflected in changes in levels of protein and/or enzymatic 
activity  
• whether any resulting gene specific changes in DNA methylation can be 
identified   
• molecular mechanisms involved  
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RESULTS & DISCUSSION 
METHODS 
Cell culture - Human gingival tissue samples are obtained with informed consent from 
patients receiving treatment for periodontitis under a protocol approved by PCOM’s IRB 
(protocol #H04-015). The gingival tissue is processed by enzymatic dispersion to produce 
primary cultures.  Cells are maintained in Eagle’s Minimal Essential Medium (EMEM) 
supplemented with 10% fetal bovine serum and antibiotic/antimycotic (penicillin, 
streptomycin, amphotericin; Gibco/BRL).  Cells between passages 3 and 5 are used for 
experiments.  
RNA Isolation and Analysis - -- Total RNA was isolated from cells untreated (Controls) or 
treated with IL-1 (10 ng/ml) or IL-6 (10 ng/ml), NS-398 (1 µM) of PGE2 (0.1-100 µM) for the 
indicated times. Two µg RNA was converted to cDNA using the High Capacity cDNA Archive 
Kit (Applied Biosystem) and Thermal Cycler Genius.  Two µl of cDNA was used with Taqman 
Universal PCR Master Mix (Applied Biosystem), and probes for detection of DNMT1, 
DNMT3a, TET1 and Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH; Applied 
Biosystem).  Real Time PCR was performed using the Applied Biosystem Prism 7000 Real 
Time PCR system.  Reactions were done in quadruplicate and results were calculated 
according to the ∆∆CT method, and normalized to levels of GAPDH.  Statistical significance 
was determined by One-way ANOVA and post-hoc Bonferroni. 
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Figure 1.  IL-1 induces DNMT1 and inhibits DNMT3a mRNA expression in HGF -- 
Total RNA was isolated from HGF cells treated with IL-1 (10 ng/ml) for the indicated 
times.  DNMT1 and DNMT3a mRNA levels were quantified by real-time PCR, 
normalized to levels of GAPDH mRNA, and expressed relative to levels in the 
untreated cells harvested at time 0.  The graph represents data from 5 independent 
experiments using HGF cultures derived from samples from 5 different individuals, 
average +/- SEM. Statistical significance was determined using One Way ANOVA with 
post-hoc Bonferroni.  * p<0.05. 
 
Figure 2.  IL-1 increases global DNA methylation in HGF 
HGF cells were left untreated or treated with IL-1 (10 ng/ml) for the indicated times.  
Levels of 5mC were measured using the MethylFlash Methylated DNA Quantification 
Kit (Epigentek), and expressed as treated relative to time 0 control.   
 
Figure 3.   PGE2 causes dose-dependent inhibition of DNMT1, DNMT3a and TET1 
mRNA in HGF – Total RNA was isolated from HGF cell cultures treated for 24 hours 
with the indicated doses of PGE2.  DNMT1, DNMT3a and TET1 mRNA levels were 
quantified by real-time PCR, normalized to levels of GAPDH mRNA, and expressed 
relative to levels in the untreated control.  The graph represents data from 4 
independent experiments using HGF derived from 4 different individuals, average +/- 
SEM. Statistical significance was determined using One Way ANOVA with post-hoc 
Bonferroni.  * p<0.05. 
  
Figure 4. IL-1 inhibition of DNMT3a expression may be partially reversed by 
inhibition of COX-2 – Total RNA was isolated from HGF cell cultures treated for 24 
hours withIL-1 (10 ng/ml), NS-398 (1 µM) or IL-1 + NS-398.  DNMT1, DNMT3a and 
TET1 mRNA levels were quantified by real-time PCR, normalized to levels of GAPDH 
mRNA, and expressed relative to levels in the untreated control.  The graph represents 
data from 4 independent experiments using HGF derived from 4 different individuals, 
average +/- SEM.  
